Ocera Therapeutics (NASDAQ: OCRX) Update: Reiterating Buy With Increased Price Target=$5

OCRX

We listened to the company's presentation at the Cowen conference today morning. The company presented some new data from the phase 2b STOP-HE trial. In the data announced earlier in January this year, OCR-002 was able to achieve statistically significant improvement in serum ammonia level over p...

We listened to the company's presentation at the Cowen conference today morning. The company presented some new data from the phase 2b STOP-HE trial. In the data announced earlier in January this year, OCR-002 was able to achieve statistically significant improvement in serum ammonia level over p...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics